AstraZeneca Could Seek New Indication For Iressa In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
The company announces withdrawal of European Marketing Authorisation Application for gefitinib in treatment of non-small cell lung cancer. FDA is expected to provide an update on the status of Iressa's subpart H approval in January or February.